Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkae094 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel strategy for the management of cytomegalovirus retinitis in immunocompromised patients using new anti-cytomegalovirus drugs.
Front Med (Lausanne)
June 2025
Department of Ophthalmology, Peking University People's Hospital, China and Beijing Key Laboratory of Ocular Disease and Optometry Science, Beijing, China.
Objectives: This study presents four cases of cytomegalovirus retinitis (CMVR) managed using a novel antiviral strategy, aiming to preliminarily assess its efficacy and safety profile.
Methods: A retrospective chart review was conducted on four patients (seven eyes) diagnosed with CMVR at Peking University People's Hospital. All patients received oral letermovir or maribavir as the primary treatment.
Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system.
Front Pharmacol
May 2025
Department of Urology, The First Hospital of Jilin University, Changchun, China.
Background: Maribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation. Despite their established utility, a comprehensive assessment of their safety profiles in real-world settings remains lacking, particularly with regards to long-term safety outcomes within a sizable cohort.
Objective: The study aims to analyze the adverse event (AE) profiles of maribavir and valganciclovir using data from the U.
Case Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke's immune-osseous dysplasia.
Front Immunol
April 2025
Pediatrics Department, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021. However, it is rarely used in pediatric patients worldwide.
View Article and Find Full Text PDFDual Resistance to Maribavir and Ganciclovir in Transplant Recipients.
Viruses
March 2025
Eurofins Viracor Clinical Diagnostics, 18000 West 99th Street, Lenexa, KS 66219, USA.
Background: Human cytomegalovirus (CMV) remains an important pathogen, especially for immunocompromised patients such as solid organ and hematopoietic stem cell recipients. Viral genomic mutations conferring drug resistance are an important impediment to effective CMV management and frequently lead to use of alternative antiviral drugs to treat CMV disease.
Methods: Results from 1459 de-identified patient samples with both UL54 and UL97 sequencing results were analyzed for ganciclovir (GCV) and maribavir (MBV) resistance mutations.
Efficacy of antimicrobials in preventing resistance in solid organ transplant recipients: A systematic review of clinical trials.
World J Transplant
March 2025
Department of Transplantation, Hospital San Vicente Fundación, Rionegro 054047, Colombia.
Background: In the absence of effective antimicrobials, transplant surgery is not viable, and antirejection immunosuppressants cannot be administered, as resistant infections compromise the life-saving goal of organ transplantation.
Aim: To evaluate the efficacy of antimicrobials in preventing resistance in solid organ transplant recipients.
Methods: A systematic review was conducted using a search methodology consistent with the preferred reporting items for systematic reviews and meta-analyses.